-
1
Peptide use among Americans is increasing, often sourced from unregulated markets without medical supervision or quality controls.
-
2
The FDA has an opportunity to regulate peptides by creating a clinician-guided framework for safe access through licensed pharmacies.
-
3
Some peptides, like insulin and GLP-1 agonists, are FDA-approved and safe, while others lack rigorous testing and operate in a gray zone.
-
4
Restricting access to gray-zone peptides may drive consumers to riskier channels, highlighting the need for structured oversight.
-
5
A proposed system would ensure quality control, patient monitoring, and informed decision-making while respecting patient autonomy.
